RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) and maintained a $5 price target.
March 25, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on HOOKIPA Pharma and maintained a $5 price target.
The reiteration of an Outperform rating and the maintenance of a $5 price target by a reputable analyst like Brian Abrahams could positively influence investor sentiment towards HOOKIPA Pharma. This endorsement suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100